secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023332
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab
--------------------------------------------------------------------------------

- Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.
- Cash and equivalents $6.2M as of June 30, 2025; expected runway into Q4 2025.
- First patient dosed in Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor tislelizumab (TEVIMBRA).
- Raised ~$5.7M gross via convertible notes and warrants in June 2025; converted to common stock and pre-funded warrants in July.
- Company expects to share initial combination trial data from first cohort later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/0001641172-25-023332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer